mm Hg) versus 'usual' (MAP = 102-107 mm Hg) blood pressure goal groups, and also divided by three randomized antihypertensive drugs (ramipril, metoprolol, or amlodipine). We scored 4 SNPs at the ADRB2 locus. Results: Haplotypes at ADRB2 predicted chronic GFR decline rate, GFR declined more slowely in individuals with haplotype-1 (-804G]173T]16Gly]27GIn), and faster in those who carried haplotype-3 (-804G]173T]16Arg]27Gln). ADRB2 genotype interacted with antihypertensive drug class to influence GFR slope (p = 0.001-0.037). We extended our findings to an independent case/control sample of Black hypertensive ESRD, in which we found that variant Gly16Arg that tagged the GFR slope-determining ADRB2 haplotype also conferred risk for the ESRD trait in Blacks. Conclusions: The GFR decline/progression rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway.
Introduction
Hypertension is a leading reported cause of end-stage renal disease (ESRD) in the United States, and AfricanAmericans are ϳ 6 times more likely to develop ESRD attributed to hypertension than Whites [1] . This unfavorable prognosis, coupled with familial aggregation of ESRD in Blacks [2, 3] , prompts investigation of the genetic risk for this syndrome [4] [5] [6] [7] .
A role for the sympathetic nervous system in progression of renal failure is increasingly understood. Activation of renal afferent chemo-and mechanoreceptors may trigger neural events in/from damaged kidneys [8, 9] . Increased efferent sympathetic traffic contributes to hypertension in animals [8] and patients with renal disease [10, 11] . Even at sub-antihypertensive doses, the adrenergic outflow inhibitor moxonidine ameliorates progressive renal damage [12] . Accumulating reports indicate that both hypertension and microalbuminuria are associated with allelic variants in the adrenergic pathway, including catecholamine biosynthetic enzymes and adrenergic receptors [13] [14] [15] [16] [17] [18] ; thus we hypothesized that such variants would also influence the rate of progression of chronic kidney disease.
The NIDDK AASK trial focused on a cohort with progressive hypertensive nephropathy, in which glomerular filtration rate (GFR) of each participant was measured every 3-6 months for 3-5 years [19] . A pilot study was performed to assess the underlying lesions in eligible participants through renal biopsy [20] . Both blood pressure (BP) goal and antihypertensive therapies were considered in the AASK 3 ! 2 block design; thus environmental (drug and goal) exposures were appropriately balanced. Therefore the AASK trial provides a unique opportunity for research on genetic factors contributing to chronic renal functional decline. We hypothesized that the GFR decline rate measured in this population is subject to genetic determination, and common variants within adrenergic pathway genes may predict GFR decline rate.
Methods

Subjects
Primary Studies in African-American Study of Kidney Disease and Hypertension (AASK) Subjects Subjects were from the AASK Study, a 21-center randomized, controlled prospective trial that has been described previously [19, 21] . Briefly, participants were 18-to 70-year-old self-identified African-Americans with hypertension, and a clinical diagnosis of hypertensive renal disease, documented by an initial GFR (by [ 125 I]-iothalamate clearance) between 20 and 65 ml/min/1.73 m 2 , urinary protein to creatinine ratio ! 2.5 g/g, and no other identified causes of renal insufficiency. Based on a 3 ! 2 factorial design, participants were randomized to one of two goal BP ranges (half to a 'usual' mean arterial pressure goal of 102-107 mm Hg, or half to an intensively lowered mean arterial pressure goal of ^ 92 mm Hg), and to double-blinded treatment with 1 of 3 antihypertensive drug classes (40% to ␤ -blockade with metoprolol, 50-200 mg/day; 40% to ACE inhibition with ramipril, 2.5-10 mg/ day, or 20% to calcium channel blockade with amlodipine, 5-10 mg/day). If the BP goal was not achieved while the participants were taking the study drug, and the dosage of each drug was increased to the maximum tolerated dose, additional unmasked drugs were added in the following recommended order: furosemide, doxazosin mesylate, clonidine hydrochloride, hydralazine hydrochloride, and minoxidil [21] .
GFR was assessed by renal clearance of [ 125 I]-iothalamate at baseline twice, then at 3 and 6 months, and then every 6 months thereafter. Serum and urine creatinine and protein were measured by a central laboratory at 6-month intervals.
In previous reports from the AASK trial [22] , initial degree of proteinuria was a strong predictor of GFR decline as well as the response of GFR to particular medications; indeed, the benefit of ACE inhibition to progression of renal disease was confined to a subgroup with less proteinuria [22] . Therefore, SNPs contributing to GFR slope were analyzed in the subgroup with baseline urinary protein/creatinine ratio (Pro_Cr) ^ 0.22 g/g (n = 580), as previously described [22] . The value of 0.22 g/g corresponds to a urine protein excretion of ϳ 300 mg/day, and divides the ϳ 2/3 of patients with the lowest ('normal' range) proteinuria from the 1/3 with highest proteinuria (the Pro_Cr parameter is skewed towards higher values, and inversely associated with initial GFR).
We were able to ascertain, consent, and prepare genomic DNA from blood leukocytes obtained from the participants in this study. Each subject gave informed, written consent to the local institutional review boards. They were aged from 20 to 70 years, 348 males and 232 females, with a baseline GFR of 51.2 8 0.5 ml/ min/1.73 m 2 . 291 participants were in the intensively lowered BP goal group, and 289 in the 'usual' BP goal group. When divided by randomized antihypertensive drug regimen, 239 participants received ramipril, 232 metoprolol and 109 amlodipine. The AASK subset reported here (n = 580) did not differ from the complete AASK cohort [19, 22, 23] in age (p = 0.408), sex (p = 0.714), initial/ entry BP (SBP p = 0.09, DBP p = 0.97), initial GFR (p = 0.09), initial urine protein/creatinine (p = 0.537-0.990, calculated separately in different BP goal and drug groups), or overall rate of progression of renal disease (chronic/post-3 month GFR slope, p = 0.9146).
The primary analysis here is based on the chronic rate of change in GFR. The GFR slope was calculated separately during the first 3 months following randomization (acute slope) and then from 3 months and thereafter (chronic slope); the chronic slope was used as the primary outcome in this study. The acute and chronic phases were distinguished because previous studies indicated that the AASK interventions (especially calcium channel blockade) have acute effects on GFR that may differ from their long-term effects on disease progression [21, 24] .
Extension: Case/Control Sample for Black Hypertensive ESRD The extension sample consisted of 301 Black hypertensionassociated ESRD cases and 305 Black controls, ascertained from North Carolina; ESRD cases were ascertained from dialysis facilities after a clinical diagnosis of hypertension-associated ESRD and absence of diabetes, based on diagnosis by treating physician and review of medical charts. Healthy controls were sampled from the general Black population. Cases and controls differed in age (p ! 0.001), cases slightly older at 54.6 8 0.75 years and 50.2 8 0.58 years for controls. Sex did not differ significantly between groups (p ! 0.862); 56% of cases and 55.3% of controls were male. BMI was intensively lowered (p ! 0.001) in cases (26.5 8 0.42) compared to controls (29.4 8 0.39), as expected for ESRD. Controls reported normal kidney function and denied a family history of renal disease. These study subjects were born in the southeastern United States and resided in North Carolina [25] .
Genomics
Single nucleotide polymorphisms (SNPs) were obtained from public SNP databases (http://www.ncbi.nih.nlm.gov/SNP) or discovered by resequencing ( table 1 a) [13] . Genomic DNA was typed using a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry system developed by Sequenom according to a published protocol [26] , by pyrosequencing [27] , or by an immobilized probe approach [28] , in which each DNA sample was amplified in a multiplex polymerase chain reaction using biotinylated primers. Each polymerase chain reaction product pool was then hybridized to a panel of sequence-specific oligonucleotide probes immobilized in a linear array. The colorimetric detection method was based on the use of streptavidinhorseradish peroxidase conjugate with hydrogen peroxide and 3,3 ,5,5 -tetramethylbenzidine as substrates. Reproducibility of genotyping was verified with 50 blinded replicate samples. SNPs evaluated in this study had minor allele frequencies of 6 4%, and all were in Hardy-Weinberg equilibrium (p 1 0.05).
Statistical Analyses
Haplotype Inference. Typing 4 common variants at ADRB2 allowed the inference of haplotypes from unphased diploid genotypes by the HAP imperfect phylogeny method (version 3.0) [29] . Frequencies are based on the number of haplotype copies present in the entire sample. * Haplotypes or pairs observed to have significant effects on GFR decline rate.
T he minor allele of a biallelic SNP is the less common allele observed in this population of AASK. The minor allele nucleotide (A = adenine; G = guanine; C = cytosine, T = thymine) or amino acid residue and its frequency are given for each SNP. 'Gene location' is the domain (e.g. coding region or intron) in which the SNP is located. All SNPs are labeled as major allele, followed by position, and followed by minor allele. Coding region SNPs resulted in non-synonymous change of amino acid, only protein residues and amino acid codon position are shown; while synonymous change of amino acid, numbers are shown as base pairs downstream (+n) from the cap site and alleles as nucleotides. SNPs in the promoter are labeled by the number of base pairs (-n) upstream from the cap (transcription initiation) site. SNPs in the 5-UTR, introns and 3-UTR are labeled by the number of base pairs downstream (+n) from the cap site. SNP ID is the unique identifier in the public dbSNP database (http://www.ncbi.nlm. nih.gov/SNP).
Progression (Chronic Slope) of GFR Loss. One-way ANOVA determined the significance of haplotype effects on chronic (after 3 months on drug) GFR decline slope (ml/min/1.73 m 2 /year). Twoway ANOVA (covariates: Pro_Cr and Mb_GFR) assessed interaction effects of drug or BP goal with SNPs on GFR slope. Statistical Package for the Social Sciences, Version 11.0 (SPSS, Inc., Chicago, Ill., USA) was used. HAP (version 3.0) was used to impute haplotypes from diploid SNP genotypes for each individual [29] .
Exact Population Admixture. African-Americans represent an admixed population with genetic contributions from both African and European biogeographic origins [30] . In order to confirm that AASK individuals with or without trait-associated genotypes were of comparable overall genetic background, and the observed associations were not simply an artifact of differential admixture between higher and lower GFR decline rate, GAMOVA (generalized analysis of molecular variance) [31] was used to test for and quantify the relationship between the overall genetic background of the subjects and quantitative phenotype GFR decline rate (chronic GFR slope), with an IBS (identity-by-state) distance matrix based on genotypes at 126 biallelic markers. The admixture analysis was done in all individuals. The population admixture in North Carolina has been reported [25] .
Results
Primary Studies in AASK Subjects
SNP Genotyping, Haplotypes, and GFR Slope. We typed 4 SNPs spanning ADRB2 (promoter, 5 -UTR, and coding region), giving rise to 4 common haplotypes and 3 diploid haplotype pairs ( table 1 b). ADRB2 variants Gly16Arg and Glu27Gln have been associated with hypertension [32] , while G-804A and C173T are in the functional proximal promoter region and 5 -UTR [33] . GFR declined more slowly in individuals with haplotype -804G ] 173T ] 16Gly ] 27Gln (haplotype-1), and faster in those who carried -804G ] 173T ] 16Arg ] 27Gln (haplotype-3) ( fig. 1 a, b) .
Effect of Antihypertensive Medication on Genetic Associations: ADRB2-by-Drug Interactions. We first explored whether diploid genotypes were equally distributed among the three drug groups; in 3 ! 3 genotypeby-drug contingency tables, there was no deviation from the null expectation for the significant genotypes or hap- We wondered if the same variants that accelerated progression of renal disease in AASK also influenced overall hypertensive ESRD risk/susceptibility in a case/control setting. Our ESRD studies targeted ADRB2 , since polymorphism here accounted for up to ϳ 39% of the interindividual variation in GFR decline slope.
At ADRB2, we focused on individual variant Gly16Arg, since that amino acid substitution uniquely 'tagged' the difference between the trait-associated haplotype pairs, with the Arg allele predicting faster downward GFR slope. In the hypertensive ESRD case/control sample ( fig. 2 ) , the Arg allele was more prominent in cases than controls (p = 0.019), and the difference persisted after permutation (p = 0.029).
Genetic Admixture. In the AASK subjects reported here, 126 biallelic markers were genotyped. GAMOVA analysis indicated that people with similar predictor variables (GFR slope, ml/min/1.73 m 2 /year) were not genetically more related to each other than expected by chance alone, in the group with lesser proteinuria (p = 0.87). Therefore, the specific adrenergic allele and haplotype frequency differences in GFR trait means that we observed cannot be attributed to differential admixture between the higher and lower GFR decline rate groups.
In the California subjects, the Pritchard-18 method, testing differences between cases and controls, did not reveal differential admixture ( 2 = 45.08, 46 d.f., p = 0.511). Likewise, a 'genetic distance' measure (Slatkin's linearized FST) calculated using Arlequin-19 failed to reveal differences between cases and controls (FST = -0.00099, p ! 0.721). Therefore, the observed CHGA allele and haplotype frequency differences cannot be attributed to differential admixture between the case and control groups [25] .
Discussion
Overview
The autonomic nervous system is a key determinant of BP and renal function. Earlier studies showed that coldinduced stress stimulates the sympathetic nervous system, causing hypertension, proteinuria and renal pathology in rats [34] , and infused catecholamines cause GFR decline and proteinuria in man [35] . African-Americans, a segment of the population at increased risk for hypertension and nephrosclerosis, display exaggerated autonomic responses to environmental stressors [36] [37] [38] [39] . Although recent genomic studies of hypertension-associated renal disease in African-Americans indicate a major role for genetic variation at the MYH9 (non-muscle myosin isoform) locus [40] , adrenergic genetic determinants of renal dysfunction in this population have also been documented [41, 42] .
Adrenergic Hereditary Mechanisms
After initial renal injury, progressive loss of renal function reflects maladaptive changes in the kidney, such as glomerular hyperfiltration. The sympathetic nervous system regulates renal as well as systemic hemodynamics. Mühlbauer et al. [43] reported that amino acid-induced glomerular hyperfiltration was abolished by bilateral renal denervation, documenting a role of the sympathetic system in regulating GFR. Selective pharmacologic reduction of sympathetic activity attenuates progression of chronic renal disease [12] . A role for heredity in control of glomerular hemodynamics was also suggested by our observation [44] that genetic risk (family history) of hypertension predicts the GFR response to amino acids.
␤ -Adrenergic Receptors
In this study, we found that ADRB2 variants affected GFR slope. At ADRB2, the trait-associated haplotypes 1 (G-T-Gly-Gln; slower GFR decline) and 3 (G-T-Arg-Gln; faster GFR decline) differed only at position Gly16Arg. The Gly16 variant undergoes enhanced agonist-promoted downregulation, whereas the Glu27 variant is largely resistant to such downregulation; Gly16 dominates functionally when both SNPs are concomitantly present [45] . Since the Gly16 variant is more prone to desensitization, it could be expected that its steady-state agonist responsiveness is lower under physiological circumstances due to tonic exposure to endogenous catecholamines; enhanced sympathetic activity in hypertensive subjects might further promote such downregulation. This consideration yields the working hypothesis that the Gly16 variant mechanistically caused less dilation, thereby decreasing glomerular hyperfiltration. Thus many observers find that Gly16 is associated with hypertension [32] , while in our study a haplotype including Gly16 predicts slower GFR decline rate. In the setting of systemic hypertension and catecholamine excess, the desensitizationresistant Arg16 variant might thereby result in afferent arteriolar dilation, with consequent hyperfiltration, predisposing to more rapid long-term GFR decline. Indeed, Nakamura et al. [46] found that ␤ 2 -receptor agonist exposure resulted in a decline of GFR in rats with ␤ 2 -receptor overexpression, an observation compatible with our findings and hypothesis. In this study, we did not measure the sympathetic nerve activity. Masuo et al. [47] reported that Gly16 allele was associated with weight gain, BP elevation and higher plasma norepinephrine levels. However, Masuo's group studied 160 young non-obese, normotensive men, which is quite different to our population.
Previously we found that ADRB1 [42] genetic variants affected GFR slope. Both ADRB1 and ADRB2 are expressed in renal arterial smooth muscle cells, while ADRB1 is also detected in mesangial cells [48] . Catecholamines acting on these receptors would dilate renal arterioles and mesangial cells, thereby regulating not only renal blood flow but also filtration surface, consequently altering glomerular capillary hydrostatic pressure, a wellknown force in progressive renal disease [49] . Genetic variation at ADRB1 and ADRB2 might affect GFR decline rate by several mechanisms: altering receptor-binding affinity, agonist coupling to effectors, or desensitization [45, 50] .
Both ADRB1 and ADRB2 signal by increasing the second messenger cAMP; thus, the GFR decline altering polymorphisms we identified at ADRB1 [42] and ADRB2 may converge on a focal point of intracellular signal transduction: cAMP. Since cAMP mediates ␤ -receptoractivated vasodilation, changes in cAMP within renal arterioles and mesangial cells are likely to be critical to control of glomerular function.
Previously we also found that genetic variation at chromogranin A (CHGA) , which plays crucial roles in sympathetic activity, predicted GFR in healthy individuals, as well as progression of hypertensive nephrosclerosis [41] . Involvement of these three genes (CHGA, ADRB1 , and ADRB2) suggests novel pathophysiological links between the adrenergic system and chronic renal injury.
Extension of Adrenergic Associations to an Independent Hypertensive ESRD Group
An exact replication of the AASK trial is unlikely, given the scope of its duration, size, intensity, complexity, and expense. Nonetheless, we sought confirmation of the role of adrenergic polymorphism in hypertensive ESRD, this time turning to the case/control design. Here we considered ADRB2 , since genetic variation at that locus influenced GFR slope. ADRB2 haplotypes that altered GFR slope differed only at Gly16Arg, with the 16Arg-bearing haplotype-3 predicting faster GFR decline. We therefore 'tagged' ADRB2 with the Gly16Arg variant, in an African-American hypertensive ESRD case/control study [25] . Gly16Arg influenced risk for hypertensive ESRD in Blacks (p = 0.019; fig. 2 ) ; indeed, the transition from control to case status resulted in a 'flip' in the major (most frequent) allele at codon 16, from Gly (control) to Arg (case). Since the codon 16Arg variant is relatively resistant to agonist-mediated desensitization [45] , one might predict that 16Arg allele carriers would exhibit afferent arteriolar dilation, with consequent glomerular capillary hypertension, predisposing to renal injury in the long term.
Conclusions and Perspectives: Pathways
We conclude that GFR decline rate in progressive renal disease is governed in part by common genetic variation within the adrenergic pathway. Thus, GFR decline (or progression of chronic kidney disease) seems to be a polygenic trait, involving pathway contributions from ADRB2, ADRB1 , and CHGA . Our results suggest new strategies for probing the role and actions of the pathway within this setting.
